Anbio Biotechnology Class A Ordinary Shares (NNNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has a cash flow conversion efficiency ratio of 0.093x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.60 Million) by net assets ($17.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Anbio Biotechnology Class A Ordinary Sha's balance sheet to measure how much of total assets are equity-financed.
Anbio Biotechnology Class A Ordinary Shares - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Anbio Biotechnology Class A Ordinary Sha earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Anbio Biotechnology Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Medistim ASA
OL:MEDI
|
0.098x |
|
Pacific Biosciences of California
NASDAQ:PACB
|
-18.889x |
|
Ratchthani Leasing Public Company Limited
BK:THANI
|
0.127x |
|
Hu Lane Associate
TWO:6279
|
0.019x |
|
Wilson Bayly Holmes Ovcon Ltd
JSE:WBO
|
0.150x |
|
Delek Automotive Systems Ltd
TA:DLEA
|
0.164x |
|
Strata Critical Medical, Inc.
NASDAQ:SRTA
|
0.012x |
|
GHCL Limited
NSE:GHCL
|
0.091x |
Annual Cash Flow Conversion Efficiency for Anbio Biotechnology Class A Ordinary Shares (2021–2025)
The table below shows the annual cash flow conversion efficiency of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Anbio Biotechnology Class A Ordinary Sha.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.16 Million | $-6.74 Million | -0.223x | -284.68% |
| 2024-12-31 | $17.19 Million | $2.08 Million | 0.121x | +99.61% |
| 2023-12-31 | $14.82 Million | $898.37K | 0.061x | -82.90% |
| 2022-12-31 | $12.55 Million | $4.45 Million | 0.355x | -78.50% |
| 2021-12-31 | $2.54 Million | $4.18 Million | 1.649x | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/… Read more